Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, closed its latest early-stage healthcare venture capital fund, Sofinnova Capital X, at €472 ($548) million.
Capital X, the 10th iteration of Sofinnova Partners’ flagship fund, was raised with institutional investors including pension funds, insurance companies, foundations, endowments, corporate investors, and prominent family offices from across Europe, Asia, and North America.
Capital X will invest in the most promising biopharmaceutical and medical device startups that address pressing unmet clinical needs and aim to transform patients’ lives. In keeping with the current strategy, the team will source and create value across a portfolio of groundbreaking innovations in healthcare, supporting entrepreneurs globally in the creation and growth of their companies.
This brings the total amount the firm has raised to €1 billion in the last 12 months across its multi-fund platform, and the total AUM to over €2.5 billion.
Led by Antoine Papiernik, Managing Partner and Chairman, and Henrijette Richter, Managing Partner, Sofinnova Partners is a European venture capital firm in life sciences, specializing in healthcare and sustainability with has over €2.5 billion under management.
FinSMEs
25/10/2021